A New Contender in the Obesity Treatment Arena

Amgen is making waves in the obesity drug market with the launch of Maritime, its ambitious Phase 3 clinical program for MariTide, the company’s most advanced obesity asset to date. The program consists of two large-scale trials aimed at evaluating the drug’s efficacy in different patient populations, marking Amgen’s most significant step yet in the fight against obesity and metabolic disorders.

MariTide: Amgen’s Novel Approach to Obesity

MariTide is a monoclonal antibody engineered to activate GLP-1 receptors while inhibiting the GIP receptor, a dual mechanism that has shown promising weight loss effects in earlier studies. Unlike traditional peptide-based GLP-1 therapies, MariTide’s approach could offer differentiated benefits, particularly in dosing frequency and metabolic effects.

Breaking Down the Maritime Trials

Amgen’s newly launched Maritime program consists of:

• Maritime-1: A Phase 3 trial for 3,500 participants with obesity or overweight without Type 2 diabetes.
• Maritime-2: A Phase 3 trial for 999 participants with obesity or overweight with Type 2 diabetes.

Both studies are placebo-controlled and will test three different doses of MariTide over 72 weeks, with the primary endpoint measuring percent change in body weight. The first data readouts for both trials are expected in early 2027, according to ClinicalTrials.gov.

What Sets MariTide Apart?

The obesity drug market has seen intense competition with the rise of GLP-1 receptor agonists like Eli Lilly’s Zepbound (tirzepatide) and Novo Nordisk’s Wegovy (semaglutide). However, Amgen believes MariTide could stand out due to its potentially improved dosing schedule and unique mechanism of action.

In its Phase 2 trial, MariTide demonstrated:

• Up to 20% weight loss over 52 weeks in individuals with obesity or overweight.
• No observed weight loss plateau, suggesting potential for greater reductions beyond the trial period.
• Strong results across multiple dosing regimens, with the 280 mg monthly group achieving the highest weight loss.

This level of weight reduction places MariTide on par with existing therapies, but its once-monthly dosing could provide an edge over weekly injections offered by competitors.

Beyond Weight Loss: A Broader Clinical Vision

Amgen isn’t stopping at obesity treatment alone. The Maritime program is expected to expand into Phase 3 trials in other metabolic and cardiovascular conditions, including:

• Cardiovascular disease
• Heart failure
• Kidney disease
• Obstructive sleep apnea

While the company has not disclosed specific timelines for these additional studies, they highlight Amgen’s strategic positioning in the broader metabolic disease landscape.

Competition and Market Implications

Given the meteoric rise of GLP-1 receptor agonists, investors are watching Amgen’s progress closely. Despite promising Phase 2 data, the company’s stock faced setbacks last year when investors expressed concerns over the drug’s differentiation from existing competitors.

Amgen has hinted at the possibility of a head-to-head trial against approved obesity treatments like Zepbound but has not confirmed plans. If MariTide can prove superior efficacy or a more convenient dosing schedule, it could disrupt the market and claim a significant share in the obesity treatment space.

Looking Ahead

With Phase 3 trials now underway, Amgen has officially entered the final stretch of clinical development for MariTide. If the Maritime trials confirm its efficacy and safety profile, MariTide could become a formidable new player in the rapidly growing obesity drug market, offering millions of patients a new treatment option.

As we sail toward 2027, all eyes will be on Amgen to see if MariTide can deliver on its promise and reshape the future of obesity treatment.